chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Itchy welts and rash on neck, trunk, arms, legs face.; Itchy welts and rash on neck, trunk, arms, legs face.; Itchy welts and rash on neck, trunk, arms, legs face.; Patchy clusters or individual spots. Last 2-3 weeks.; This is a spontaneous report from a contactable consumer (patient herself). A 74-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection; Batch/Lot Number: EL9267), via an unspecified route of administration, administered in Arm Left on 03Mar2021 13:00 as SINGLE DOSE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot: unknown;) for COVID-19 immunisation. The patient experienced Itchy welts and rash on neck, trunk, arms, legs face. Patchy clusters or individual spots. Last 2-3 weeks on 05Mar2021 07:00. The outcome of the events was not recovered.  No follow-up attempts are possible. No further information is expected.
a 87 y.o. who was brought in by her daughter to the ED with concern for vision loss, altered mentation with last known normal the previous evening. Patient denies experiencing vision loss right now. Denies headache, changes in speech, dysphagia, extremity weakness or sensory deficit that is new from baseline.  ED provider noted left sided visual field deficit and some left sided neglect, CT head demonstrated right frontal hypodensity concerning for developing infarct. Patient had a 10-minute episode of dysarthria approximately one month prior on 10/4 and she was started on ASA and Plavix DAPT for high-risk TIA. After 21-days she was continued on Plavix alone, however on 11/2 she was seen by her PCP  with concern for worsening anemia (hemoglobin 6.4). She was asymptomatic. Patient received 2 units PRBC and sent home with GI referral, and her Plavix was stopped.    Had an ECHO 10/8 with EF 65-70%, mild diastolic dysfunction, left atrium size mildly dilated. No evidence of thrombus. Was recommended to have MCOT and neurology follow-up, however this has not yet been completed
no adverse event; Improperly stored administered vaccines; This spontaneous report was received from a registered nurse and from vaccine coordinator and refers to a patient of unknown age and gender. The patient's concurrent conditions, historical conditions and concomitant medications were not reported.   On 14-SEP-2021, the patient was vaccinated with improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # T041687 expiration date 10-DEC-2022 (dose, route of administration and anatomical location were not reported) for prophylaxis (product storage error). The suspect vaccine was stored in a temperature from -10 degree Celsius (C) to 8 C for 5 hours and 10 minutes. There was previous temperature excursion - the vaccine was stored in a temperature from -10 C to 8 C for 8 hours and 41 minutes and for 3 hours and 35 minutes. No additional adverse events were reported (no adverse event).   This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2110USA005066: US-009507513-2109USA006582: US-009507513-2109USA006583: US-009507513-2109USA006584: US-009507513-2109USA006585: US-009507513-2109USA006586: US-009507513-2109USA006587: US-009507513-2109USA006588: US-009507513-2109USA006589: US-009507513-2109USA006590: US-009507513-2109USA006591: US-009507513-2109USA006593: US-009507513-2109USA006594: US-009507513-2109USA006595: US-009507513-2109USA006596: US-009507513-2109USA006597: US-009507513-2109USA006537:
rash on thighs bilat external surface was bumpy;sl reddened & fading;no local swelling or tenderness;
Per Client received first dose of Moderma vaccine in left arm on Thursday 2/24/2021 at 0920. On Saturday 2/27/2021 at 6:20 pm, starting experiencing itching on legs and scalp. Per Client the itching worsened as it continued on legs, scalp and started to happen throughout body, including arms, neck and back with redden skin along with welts. Per Client received vaccines in past with no complications. Client reported that symptoms have subsided some, after taking Hydroxyzine and Tylenol. Per Client has already consult a MD via a virtual appointment and forwarded information through MYChart to PCP.
Left deltoid triceps red, diffusely injected and warm. No drainage at site. Child stable; no cellulitis
Vaccine that administered beyond use date after the thaw process; This spontaneous case was reported by a paramedic and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process) in a 34-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027H21B) for COVID-19 prophylaxis.     It was unknown whether patient has diagnosed/tested positive for COVID-19. It was reported acute illness at the time of vaccination and up to one month before and chronic or long-standing health conditions were unknown.     On 27-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On 27-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine that administered beyond use date after the thaw process) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient age was reported as 34 years and 9 months old.  No concomitant medication information was provided.  The vaccine were administered beyond use date after the thaw process. Patient received Moderna COVID-19 vaccine for dose 1. Reporter stated that there was no patient that had any adverse reactions and there were no reports of any reactions after the administration of vaccines.   Patient got Moderna with vaccine Ndc code 80777-0273-99.  No treatment medication information was provided.
Immediately felt weakness in arm/hand of injection with tingling in hand. Minutes later tingling in left foot.  Tingling continues to occur but less frequently.  Early morning the next day (4/13) had chills and fever. Fever continued through early afternoon.  On 4/19 both feet felt like they were on fire and the soles itched like crazy.  Went away after an hour.  Around 5:30 am red spots appeared on the bottoms of feet which were very warm.  This went away.  Throughout the day I had red spots on my feet and legs that would be red, warm, and some itchy that would come and go.  My thighs had spots that appeared to be heat rash. At 7:30 pm areas on feet were bright red, warm and slightly swollen.Diagnosed with allergic
2 days after immunizations the child was brought back to clinic mod. edema entire left thigh, no limp, skin sl. discolored. Deeper pink than right, pruritic left thigh.
Starting a few hours after receiving the vaccine, my arm started hurting and I felt really bad. I couldn't move, get up or do anything. I felt like I had the flu or COVID x 3. I couldn't move or eat, sensitive to temps, had a headache and had fever/chills. I went to work the next day but I still felt poorly. These symptoms lasted about 3 days, and the arm soreness lasted for about a week. I ended up catching COVID and testing positive 01/19/2022. I was sick from the 17th of January (when I started feeling poorly) until the 28th of January. I still experience symptoms and am having trouble functioning to this day. I am having to use an inhaler and breathing treatments (which I never had to do before).
Headache & NauseaVomiting Narrative:  After 2nd vaccine, headache, nausea with vomiting, stabbing muscle pains for over 8 hours, fatigue, muscle pain, stiffness and weakness lasting 48 hours. Bloody Urine with small clots approx. 30 hours after injection. (This was a new issue.) Called PCP concern for Rhabdo.Kidney pain, liver discomfort, fever up to 101, starting 8 hours after injection until 50 hours after injection. Pain and Swelling at the injection site.
received dose at age of 49; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 49-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   In August 2022, the patient received the 1st dose of Shingrix (intramuscular). In August 2022, unknown after receiving Shingrix, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown.   Additional Information: GSK receipt date: 22-FEB-2023 Reporter's comment: The reporter was the health care professional (medical assistant).  The patient was immunocompetent. Nothing else was reported.  The reporter consent to follow up. Additional Supportive Information: A 49 year old patient received Shingrix dose, which led to inappropriate age at vaccine administration.
Initial onset of severe pain to vaccination site that has not resolved. Severe swelling at injection site, continued severe pain; arm tender, red and muscle rigid; unable to move shoulder without severe pain. Swelling observed 8/24/13 AM by patient.
Day of shot was fine. Vomiting, lethargy, feeling sick, sleeping a lot and unable to eat the day following the shot.  2nd and 3rd day headache, indigestion and general malaise continue.
She received the vaccination around 11:30 am on 11/30/2017.The patient noticed symptoms that same evening around 6 or 7 pm. Her symptoms included redness of the upper left arm, pain, swelling, and itchiness. She called her doctor's office and has since taken ALEVE and BENADRYL and symptoms are improving. She has had no limited movement, just pain. No appointment has been made at this point.
Day One for 18 hours chills, severe aches and pains, severe joint pain and stiffness, headache, nausea,weakness.  Day two all of those symptoms resolved except for chills and weakness, New symptoms of  shaking, diarrhea, and sweats.  Mostly resolved at 36 hours after vaccine.
Information has been received from a physician concerning a patient who within the last month (in September 2011), was vaccinated with a dose of ROTATEQ (Lot # not reported). It was reported that immediately following the dose, the patient had excessive diarrhea. The physician did multiple tests to rule out other illness and no one in the patient's family had been ill at that time. The physician stated that it took several weeks for the diarrhea to clear up. Follow up information has been received from physician, concerning an approximate 17 weeks female patient who on 31-AUG-2011 was vaccinated orally with the second dose of ROTATEQ (Lot number 669992/0287AA). Concomitant vaccine given on the same day included the second dose of PREVNAR (Lot number 916973) administered in the left arm and the second dose of PENTACEL (Lot number C3796AA) administered in the right arm. The physician indicated that that patient presented between 01-SEP-2011 or 02-SEP-2011 with diarrhea for 1 month, watery, 4 to 5 stools per day, there was blood on single occasion; onset shortly after 4 hours given ROTATEQ. E. coli urinary tract infection (UTI) developed 2 weeks after onset. On 20-SEP-2011, the following lab tests were taken: Campylobacter culture (No enteric Campylobacter isolated), stool Escherichia coli 0157:H7 culture (No detected), stool Salmonella and Shigella culture (No Salmonella or Shigella isolated), Rotavirus Ag (Negative), Red subst, faces (1+), stool occult blood test (Negative ), Giardia EIA (Negative), Cryptosporidium EIA (Negative) and histolytics Stool EIA (Negative). It was reported that the patient did not seek medical attention. In October 2011, the patient recovered from the events. No further information is available.
This initial non-serious spontaneous case, was received on 01-Nov-2017, from a physician, concerning an adult male patient of unspecified age. This refers 47 of 84 patients. On an unspecified date in Oct-2017 (between 25-Oct-17 to 27-Oct-17), the patient was administered with AFLURIA (TIV) Thiomersal (batch number: 14649211A, dose, route of administration, anatomical location and expiry date: not reported). It was reported that, the vaccine was stored in cooler with ice packs for 6 days and had reached unknown temperature during transport instead of storing at 36-degree F and 46-degree F (2-degree C and 8-degree C). And the same was administered to the patient. The reporter stated that the temperature was not monitored on 24-Oct-2017 (could have been between 2-8C, but not certain) and there were no reports of adverse effect after vaccination. The vaccine had been discarded. Follow up received on 09-Nov-2017 from a physician: Added event (no adverse effect) and reporter's comment. Amended narrative accordingly.
feels cold; absolutely shivering; Sore Arm; A spontaneous report was received from a consumer concerning a 60 years old, male patient who developed Sore Arm/ Pain in extremity , absolutely shivering/ Chills , feels cold/ Nasopharyngitis.    The patient's medical history was not provided. Additional suspected products included Metformin, Dertin, Omeprazole, Insulin, Aspirin, Vitamin D.    The patient received their first of two planned doses of mRNA-1273 (Batch number not provided) on 20-Jan-2021. On 20-Jan-2021, approximately few hours prior to the onset of the symptoms, the patient received their first of two planned doses of mRNA-1273 (Batch number not provided) intramuscularly for prophylaxis of COVID-19 infection.    Patient had a sore arm last night and today he is absolutely shivering, he has three blankets on and still feels cold. Treatment information was unknown.    Action taken with mRNA-1273 in response to the event(s) was not provided.  The outcome of the events were unknown.
throat condition improved; throat condition improved; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 04May2021 (Batch/Lot number: unknown) at the age of 66 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Asthma" (ongoing); "Anxiety" (ongoing); "High Blood Pressure" (ongoing). Concomitant medication(s) included: ATENOLOL taken for hypertension (ongoing); LISINOPRIL (ongoing); BUSPIRONE taken for anxiety (ongoing); CLONIDINE; CITALOPRAM; CLONAZEPAM taken for anxiety; ADVAIR taken for asthma. The following information was reported: THERAPEUTIC RESPONSE UNEXPECTED (non-serious) with onset 05May2021, outcome "recovered" (May2021), PRE-EXISTING CONDITION IMPROVED (non-serious) with onset 04May2021, outcome "recovered" (May2021) and all described as "throat condition improved".  Additional information: Patient has had a build up of phlegm in his throat for about 3 months.  He received his first dose of the Covid-19 vaccine on 04May2021 and the phlegm in his throat is now gone he was so amazed and doesnt know whats in the Covid-19 vaccine but whatever it is its good. He feels so much better. He did not go to see his doctor about the phlegm in his throat because he thought the phlegm would clear up by itself. He cant wait until his next dose of the Pfizer Covid-19 vaccine. about 2.5 hours after he received the first dose of the Covid-19 vaccine, the phlegm in his throat cleared up. He has been taking all his medications for years. He looked up phlegm in the throat on the internet and has been gargling with warm salt water per the recommendation he found. The phlegm has been gone since he had the Covid-19 vaccine yesterday.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Fever, chills and headache. Localized swollen, erythematous and pain at site of injection.
This spontaneous report as received from a healthcare worker (Master of Science in Nursing) refers to his 14 year old female daughter who is the patient. Reported stated that the patient got 2 doses of GARDASIL (dates were not reported), dose, route of administration, lot numbers and expiration dates were not provided. Reporter stated that pharmacist told them the series needed to be restarted, since the third dose would be late. The patient has restarted the series, and now (exact dates were not reported) have received 2 additional doses of GARDASIL, dose, route of administration, lot numbers and expiration dates were not provided. No adverse effects reported. This is one of several reports from the same source. Additional information is not expected, because the reporter did not wish to be contacted.
Freezing cold; Chills; This spontaneous case was reported by a consumer and describes the occurrence of FEELING COLD (Freezing cold) and CHILLS (Chills) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No relevant concomitant medications reported No relevant medical history was reported.    On 04-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On 04-Mar-2021, the patient experienced FEELING COLD (Freezing cold) and CHILLS (Chills). At the time of the report, FEELING COLD (Freezing cold) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment Medications were not provided by the reporter.
Tenderness; Very hot to the touch at injection site; Swollen at injection site; Red at injection site which feel like they are getting worse and feels like a sunburn; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (Tenderness), VACCINATION SITE WARMTH (Very hot to the touch at injection site), VACCINATION SITE SWELLING (Swollen at injection site) and VACCINATION SITE ERYTHEMA (Red at injection site which feel like they are getting worse and feels like a sunburn) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. G07B21A) for COVID-19 vaccination.     The patient's past medical history included COVID-19 in January 2021. Concurrent medical conditions included Allergy to antibiotic. Concomitant products included LISINOPRIL, SIMVASTATIN, HYDROCHLOROTHIAZIDE and ESTRADIOL for an unknown indication.    On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Mar-2021, the patient experienced TENDERNESS (Tenderness), VACCINATION SITE WARMTH (Very hot to the touch at injection site), VACCINATION SITE SWELLING (Swollen at injection site) and VACCINATION SITE ERYTHEMA (Red at injection site which feel like they are getting worse and feels like a sunburn). At the time of the report, TENDERNESS (Tenderness) was resolving and VACCINATION SITE WARMTH (Very hot to the touch at injection site), VACCINATION SITE SWELLING (Swollen at injection site) and VACCINATION SITE ERYTHEMA (Red at injection site which feel like they are getting worse and feels like a sunburn) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included Benadryl and  ice pack
Pt reported SE on 3/17/16: site of inj red (golf ball size), warm to touch, with hard ball feeling at site of inj.
Vestibular disorder--dizziness, unbalanced, tinnitus, nausea
Pt is 17 years old and was given a first dose of Moderna vaccine at the pharmacy, she presented for her second dose to a clinic at which time the mistake was identified.  A second dose of Moderna was administered on 8-18-21 per recommendation from CDC when 1st dose is given to an underage person by mistake.
flu like symptoms; This is a spontaneous report from a contactable pharmacist received via a Pfizer sales representative. This pharmacist reported similar events for three patients. This is the second of three reports. A patient of unspecified age and gender received pneumococcal 13-valent conjugated vaccine (diphtheria crm197 protein) (PREVNAR 13, lot number and expiry date unknown) and influenza vaccine (FLU), both via an unspecified route of administration on an unspecified date at a single dose for immunization. The patient's medical history and concomitant medications were not reported. The pharmacist reported that the patient experienced side effects from receiving pneumococcal 13-valent conjugated vaccine (diphtheria crm197 protein) and flu together on an unspecified date. The patient experienced flu like symptoms for 2 days. The outcome of the event was unknown.  No follow up attempts are possible, information on the lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2019438279 same reporter, same product, same event, and different patient;US-PFIZER INC-2019438282 same reporter, same product, same event, and different patient
Starting with intense itching and uticaric rash and migraine 2 days following. Continued migraine and 4 days following, rash change from uticaric into a vesicular rash on ankles, blistering of mucosal membranes in mouth and eye irritations. Treated at home with diphenhydramine, certizine, naproxen, sumatriptan, caladryl lotion, mouth sores with debacteral, salt water and diphenhydramine rinses, Eyes with neomycin and dexamethasone ointment and keto fumarate.  With some relief.  Prednisone and mycolog started 9 days following taken until day 12 following.  (Severe neck pain and fatigue day 13-15-possibly not related.)